NCT04736602View on ClinicalTrials.gov

Efficacy and Safety Study of Triptorelin 3-Month Formulation in Chinese Children With Central Precocious Puberty.

PHASE3CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

March 27, 2021

Primary Completion Date

February 9, 2022

Study Completion Date

September 3, 2022

Conditions
Central Precocious Puberty
Interventions
DRUG

Triptorelin pamoate 15mg

Intramuscular injection (IM)

Trial Locations (7)

210008

Children's Hospital of Nanjing, Nanjing

214023

Wuxi Children's Hospital, Wuxi

330006

Jiangxi Provincial Children's Hospital, Nanchang

430030

Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan

450018

Henan Children's Hospital, Zhengzhou Children's Hospital, Zhengzhou

610073

Chengdu Women's and Children's Central Hospital, Chengdu

063000

Tangshan Maternal & Child Health Hospital, Tangshan

Sponsors

Lead Sponsor

Ipsen
All Listed Sponsors
lead

Ipsen

INDUSTRY